Reports Q1 revenue $69.222M, consensus $70.17M. “In the first quarter, we made great progress across a number of our strategic objectives that support both the near- and long-term growth of Mirum while maintaining a strong financial position,” said Chris Peetz, chief executive officer at Mirum. “Our commercial business is performing well, and we saw continued growth in demand for LIVMARLI globally putting us on track for our total revenue guidance target for the year. The FDA’s approval of LIVMARLI for cholestatic pruritus in patients with PFIC was also an important step in bringing our high impact medicines to the rare disease patient community. We look forward to continuing this momentum with our upcoming NDA submission for CHENODAL in CTX, and important interim analyses in our PSC and PBC studies in June.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum data published in Lancet shows benefits of Livmarli in PFIC
- Mirum Pharmaceuticals initiated with a Buy at Stifel
- Mirum Pharmaceuticals participates in a conference call with JPMorgan
- Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink
- Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment
Questions or Comments about the article? Write to editor@tipranks.com